Veradigm | MDRX - Cash And Equivalent


Veradigm reported $492.6M in Cash and Equivalent for its fiscal quarter ending in September of 2022.





Cash And Equivalent Change Date
Alcidion AUD 11.8M 2.84M Jun/2024
Ambu A/S DKK 691M 44M Mar/2026
Amplifon EUR 308.88M 71.57M Dec/2025
Cardinal Health USD 3.94B 1.16B Mar/2026
Centene USD 21.26B 3.38B Mar/2026
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Cigna USD 7.04B 636M Mar/2026
Coloplast 911M 497M Sep/2023
Computer Programs Systems USD 24.85M 4.93M Dec/2025
Convatec Group USD 64.7M 32.2M Dec/2024
CVS Health USD 9.54B 1.09B Mar/2026
Diasorin EUR 173.08M 3.51M Jun/2025
Elevance Health USD 9.66B 166M Mar/2026
General Electric Aerospace USD 10.98B 1.41B Mar/2026
Gulf Medical Proj AED 74.52M 101.52M Mar/2025
Humana USD 4.95B 751M Mar/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Laboratory Of America USD 981.1M 448.8M Mar/2026
Maximus USD 157.45M 19.86M Mar/2026
McKesson USD 3.98B 1.02B Mar/2026
Med Life RON 185.35M 35.79M Sep/2025
Molina Healthcare USD 5.31B 1.07B Mar/2026
Omnicell USD 239.22M 42.7M Mar/2026
Oriola-kd EUR 107.6M 13.9M Sep/2025
Owens Minor USD 336.88M 54.89M Mar/2026
Quest Diagnostics USD 393M 27M Mar/2026
Rede D'or Sao Luiz BRL 5.41B 1.7B Mar/2026
Siemens Healthineers EUR 2.14B 231M Dec/2025
Sonova Holding CHF 413.9M 134.3M Jun/2023
Supermax Corporation Bhd MYR 855.25M 11.02M Sep/2025
UnitedHealth USD 31.23B 3.11B Mar/2026
Veeva Systems USD 1.42B 238.9M Dec/2025
Veradigm USD 492.6M 7.57M Sep/2022
Xerox USD 585M 73M Mar/2026